NEWS & MEDIA

  • News

News

Home>NEWS & MEDIA>News

Leupia released in prefilled syringe form
Day : 2010-11-17

progesterone injection

progesterone ovule

- The only insured hormone product for sexual precocity




Daewoong Pharmaceutical Co., Ltd (President Lee Jong Wook) announced that its ampoule type Leupia was changed to a prefilled syringe. This will prevent any mixing due to the opening of glass ampoules

Leupia is excellent for the treatment of prostate cancer, breast cancer and sexual precocity, and is the only insured hormone product for sexual precocity. This is because Leupia can control theadministration amount by adding injector with gradation. Kim, Hyowoong, Leupia PM manager said, "It is important to control the amount when using hormone products. It must have safety, as it is targeted to youth and administered for 2 to 5 years."

Leupia is excellent in the treatment of prostate cancer, breast cancer, fibroid, and endometriosis. In particular, it has no anaphylactoid reactions (urticaria, RDS and edema) as it is made through a spray-dried method, the first of its kindin the world. It is highly recognized for its safety and lack of side effects, as it does not use Methylene Chloride.

Spray-dried method: This is a technology to make spray type drug, in which the drug is released to the body slowly, and was developed by Daewoong Life Science Research Center with Peptron, a bio venture company.

Prefilled syringe: Solvent suitable for one injection is filled.

Prev License agreement of hemostatic for operation with 3D Matrix in Japan
Next Completed 1st clinical test of the first neuropathic pain killer developed in Korea
목록